Platelet reactivity in an elderly and healthy population

DOI Web Site
  • Chan Melissa V
    The Blizard Institute, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, UK
  • Barwari Temo
    King's British Heart Foundation Centre, King's College London, UK
  • Huffman Daniela
    The National Heart, Lung and Blood Institute's Framingham Heart Study, USA
  • Armstrong Paul C
    The Blizard Institute, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, UK
  • Santer Peter
    Department of Laboratory Medicine, Bruneck Hospital, Italy
  • Kiechl Stefan
    Department of Neurology, Medical University Innsbruck, Austria
  • Willeit Johann
    Department of Neurology, Medical University Innsbruck, Austria
  • Mayr Manuel
    King's British Heart Foundation Centre, King's College London, UK
  • Johnson Andrew D
    The National Heart, Lung and Blood Institute's Framingham Heart Study, USA
  • Warner Timothy D
    The Blizard Institute, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, UK

抄録

<p>Background</p><p>Cardiovascular disease (CVD), including myocardial infarction (MI) and stroke, is the largest cause of morbidity and mortality worldwide. CVD is intrinsically linked to hemostasis and thrombosis and, therefore, platelet reactivity. As such, secondary prevention of CVD usually includes inhibitors of platelet function. Though the majority of CVD patients are over the age of 65, large healthy population studies of platelet reactivity have been performed in younger (<40) volunteers. The Bruneck Study is unique in that all participants are over the age of 65. Therefore, the aim of this study was to phenotype platelet reactivity in this elderly population.</p><p>Methods</p><p>Fasting blood was taken from 338 people into citrate (0.105M) anti-coagulant and platelet rich (PRP) and poor (PPP) plasma was obtained by centrifugation. All experiments were performed within 2 hours of blood draw. Traditional light transmission aggregometry (LTA) in response to arachidonic acid (AA), ADP, collagen, TRAP-6 amide and U46619 was performed. In addition, platelet aggregometry was also assessed using the Optimul plate-based method in response to AA (0.3-1.5mM), ADP (1-30µM), collagen (0.4-30µg/ml), epinephrine (0.6-10µM), ristocetin (0.1-1.5mg/ml), TRAP-6 (0.1-25µM) and U46619 (0.01-10µM). % aggregation was calculated and data were analysed using R with the nlpr package and GraphPad Prism. Data is reported as mean±sem.</p><p>Results</p><p>The cohort was evenly split between sex (49% female) with a mean age of 76.1±7.1 years. There was a low incidence of MI (4.7%), stoke (6.5%) and diabetes (6.2%). Concentration-response curves for Optimul aggregometry were generated and final % aggregation was compared to LTA (LTA vs Optimul, respectively): AA 1mM (29±2% vs 68±2%), ADP 5µM (54±1% vs 77±1%), ADP 20µM (59±1% vs 80±1%), collagen 0.4µg/ml (34±1% vs 76±1.2%), 4µg/ml (59±1% vs 81±1%), 10µg/ml (58±1% vs 80±1%), TRAP-6 25µM (62±1% vs 87±1%), U46619 10µM (63±1% vs 84±1%).</p><p>Conclusions</p><p>This is the first extensive platelet reactivity using multiple concentrations of a broad range of agonists in a large, healthy, elderly population. Subgroup analyses will allow us to determine whether there are any associations with platelet reactivity, age, and cardiovascular disease.</p>

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ